Effect of Oxytocin Antagonist on Reduction of Uterine Contractions

NCT ID: NCT01043120

Last Updated: 2017-06-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 99 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2010-12-31

Brief Summary

The main purpose of this clinical research trial was to evaluate the effects of barusiban compared to placebo on uterine contractions on luteal phase uterine contractions in oocyte donors supplemented with progesterone.

Detailed Description

This was a randomised, double-blind, parallel groups, placebo-controlled, multi-centre trial. It was designed to evaluate the efficacy of barusiban, a selective oxytocin antagonist, on reducing the frequency of uterine contractions on the day of embryo transfer.

Participants in this trial were oocyte donors who had undergone controlled ovarian hyperstimulation in the long gonadotrophin-releasing hormone (GnRH) agonist protocol or the multiple-dose GnRH antagonist protocol, had received human chorionic gonadotrophin (hCG) for triggering of final follicular maturation and had undergone oocyte retrieval (OR) with a yield of ≥ 6 cumulus-oocyte-complexes. The duration of the trial was two days: Day OR +2 (screening, randomisation and dosing of investigational medicinal product) and Day OR +3 (end-of-trial).

On Day OR +2, participants were screened and subsequently randomised to barusiban or placebo. All participants received an intravenous (IV) bolus for 1 minute followed by an IV infusion for up to 59 minutes, administered via an indwelling catheter, of barusiban or placebo. Bolus volume and infusion rate were identical for barusiban and placebo. A mock embryo transfer (MET) procedure was performed 40 minutes after start of dosing and included intrauterine administration of a non-radioactive ultrasound contrast agent (SONOVUE) via the embryo transfer catheter. Transvaginal ultrasound of around 5 minutes duration was performed at seven time points on Day OR +2 and covered a span of approximately 2.5 hours including pre-dosing, during dosing, before and after mock embryo transfer, and post-dosing. The transvaginal ultrasound recordings were analysed for frequency of uterine contractions and other uterine contractility parameters by a central independent assessor, blinded to treatment allocation. Movement of the ultrasound contrast agent after the mock embryo transfer procedure was evaluated by the central independent assessor.

As an attempt to document the impact of uterine contractions on potential embryo expulsion, an exploratory evaluation of the movement of an ultrasound contrast agent (SONOVUE)administered intrauterinely via an embryo transfer catheter during the mock embryo transfer was performed. The anatomical point of release of the ultrasound contrast agent (correct or incorrect deposition site, and estimated distance from fundus) as well as any immediate movement (yes/no) of the bolus was recorded by the central independent assessor.

Definitions:

The frequency of uterine contractions was defined as the number of uterine contractions per minute. A contraction was defined as one sequential upward and downward vertical displacement of the endometrial / myometrial interface over time. The frequency was the inverse of period converted to contractions per minute.

The period was the average time it took to complete one contraction during the studied time interval. It was calculated from both the peaks and the troughs at the anterior and posterior endometrial /myometrial interfaces. The period was measured in seconds per contraction.

The external contractile measure was the mean wave amplitude in mm at the lumenal surface. This metric was measured at the lumenal peaks and troughs only and was a measurement designed to study the relationship between endometrial wave activity, manifest as bulk motion of the uterus, versus internal contractile strength. The external contractile measure was reported in mm/contraction. The external contractile measure quantified the movement of the uterus as a whole as measured at the lumen, i.e. the motion of the uterus relative to the body.

The internal contractile measure was the strength of the contractions based upon the sum of the contraction amplitudes measured at the anterior and posterior endometrial / myometrial interfaces. The amplitude at each interface was defined as the average difference between the endometrial / myometrial-lumenal distance measured at the peaks and troughs of the endometrial / myometrial interfaces. The internal contractile measure was reported in mm/contraction. The internal contractile measure quantified the movement of the endometrium relative to the lumen, i.e. the motion internal to the uterus.

The total contractile measure was the sum of the external contractile measure and the internal contractile measure and quantified total muscle movement in the uterus. If the waves at the anterior and posterior endometrial / myometrial interfaces were in phase then there was no endometrial motion relative to the lumen and the motion was a pure wave motion with the internal contractile measure equal to zero. The total contractile measure was reported in mm/contraction.

Inter-subendometrial space was measured clinically as the distance between the anterior stratum basalis and posterior stratum basalis layers in mid-sagittal plane at an anatomic location between 5 and 10 mm from the fundus. All clinical inter-subendometrial space measurements were made by selecting a clear image of the uterus, waiting for any contractions to pass and freezing the image.

A linear distance measurement was then taken between the anatomic landmarks described above. Inter-subendometrial space was calculated from existing measurements using the mean of all measurements identifying the endometrial-myometrial interfaces on the superior and inferior surfaces in each endometrial strip when the arrows identifying endometrial contractions were placed for motion analysis. Inter-subendometrial space was reported in mm.

The direction of wave propagation was classified as one of the following:

• Fundal (from cervix to fundus)
• Cervical (from fundus to cervix)
• Convergent (opposing) starting simultaneously from cervix and fundus
• Focal local contractions (which are not involving the whole uterine walls)
• No activity
• NE: not evaluable At each assessment time point, the most predominant type of direction of wave propagation was recorded.

Dispersion of the ultrasound contrast agent bolus after release from the catheter was recorded as yes/no and number of dispersed fragments, if applicable.

Location of the ultrasound contrast agent bolus was categorised as follows:

• Upper 1/3 (fundal) part of uterine cavity
• Central 1/3 of uterine cavity
• Lower 1/3 (cervical) part of the uterine cavity
• Intralumenal part of Fallopian tube
• Intra-cervical
• Vaginal
• NE: not evaluable Distance from the apex of the fundus at the myometrial-endometrial interface to the position of the microdroplet of ultrasound contrast agent was recorded in mm.

Velocity of the bolus of ultrasound contrast agent was assessed from distance and time, and was recorded in mm/hour.

Conditions

In Vitro Fertilisation (IVF) Treatment

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Barusiban

Group Type: EXPERIMENTAL

Barusiban

Intervention Type: DRUG

IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.

Interventions

Barusiban

IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.

Intervention Type: DRUG

Placebo

IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Participants were excluded in case of endometriosis stage I-IV or uterine pathology. Participants were willing to not have intake of alcoholic beverages during the trial, to not have sexual intercourse during the trial, and to either maintain sexual abstinence or use a highly effective method of contraception from end-of-trial till onset of next menses.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 37 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Development Support

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

UZ Brussel

Brussels, , Belgium

IVF Institute

Pilsen, , Czechia

ISCARE IVF a.s.

Prague, , Czechia

IU Dexeus

Barcelona, , Spain

IVI Madrid

Madrid, , Spain

Countries

Belgium; Czechia; Spain

Other Identifiers

2009-012323-29

Identifier Type: -

Identifier Source: secondary_id

FE200440 CS11

Identifier Type: -

Identifier Source: org_study_id